EMILY ROSS: Open Payments
NPI 1083189336 · BUFFALO, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$454 in 21 payments from 10 companies in 2025. Trend: 2023 $417 · 2024 $530 · 2025 $454
Food & beverage: $454
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 4 | $127 |
| Lundbeck LLC | 4 | $72 |
| Otsuka America Pharmaceutical, Inc. | 2 | $52 |
| Corium, LLC | 3 | $49 |
| ABBVIE INC. | 3 | $47 |
| Vanda Pharmaceuticals Inc. | 1 | $30 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
Products named: INGREZZA, REXULTI, Azstarys, VRAYLAR, FANAPT, AUSTEDO XR, Qelbree, Jornay PM.
Industry payments across NY — which companies pay providers there.
